A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Akura Medical, A New Shifamed Portfolio Company, Closes $25M in an Oversubscribed Series A1 Financing

Company to accelerate development of its next-generation thrombectomy device for patients with venous thromboembolism

Akura Medical, Inc., a Shifamed portfolio company, announced today the closing of its $25M Series A1 financing, which will be used to support the development of its next-generation thrombectomy device. The financing was led by Cormorant Asset Management, with participation from The Capital Partnership (TCP), PA MedTech VC Fund and Shifamed angel investors.

“Venous thromboembolism (VTE) is a large market that is currently underserved due to limitations of existing treatment options,” stated Bihua Chen, Founder and Managing Member of Cormorant Asset Management. “We are excited to lead this round and believe there is ample room for improvement over existing treatments. Akura Medical’s differentiated technology has the potential to overcome these shortcomings with its elegant mechanical thrombectomy solution.”

VTE includes both deep vein thrombosis (DVT), a blood clot in a deep vein, as well as pulmonary embolism (PE), which occurs when a DVT breaks free and travels to the lungs, blocking some or all blood supply. Annually in the U.S., there are roughly 900K VTE cases which contribute to 100K patient deaths.1 Recently, mechanical thrombectomy devices have been used to treat high-risk VTE patients; however, current options are inefficient, procedurally complex, can result in significant blood loss, and have difficulty reaching the target anatomy.

“Akura Medical’s mechanical thrombectomy device is designed to simplify the procedure and integrate various mechanisms to efficiently and effectively remove blood clots,” commented Amr Salahieh, Founder of Shifamed and Chairman of the Board of Akura Medical. “We are extremely pleased to close this oversubscribed round of financing. The strong interest from investors validates the clear unmet need in this space and we look forward to expanding our world-class team as we drive towards the next development milestones.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy